This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Will the failure of Celladon's Mydicar gene therapy bring other high-flying gene therapy stocks down to Earth?
4/26/15 8:45PM
Catalyst and Jacobus Pharma are racing to secure FDA approval for a drug to treat a rare muscle-wasting disease.
4/24/15 12:05PM
None of the sugar-coated analyses presented at a meeting suggest the eventual outcome of Genfit's phase III study will be any better than the phase II study.
4/24/15 9:12AM
Santhera is scheduled to meet with the FDA in the next few weeks, after which it expects to submit idebenone for approval by the middle of the year.
4/23/15 10:01AM
It's common for drug companies to raise the price of their existing products once or twice per year, every year. The price increases far outpace the rate of inflation.
4/22/15 10:18AM
Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.
4/21/15 7:48AM
Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.
4/20/15 10:22AM
The positive phase I safety study was conducted using a CAR-T therapy from Novartis and the University of Pennsylvania.
4/19/15 12:45PM
New Keytruda data presented for the first time shows an overall response rate of 19% and a median duration of response exceeding one year in lung cancer patients.
4/19/15 8:30AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
4/17/15 5:59AM
In which Musk learns how to put a happy spin on failure from biotech CEOs.
4/16/15 9:07AM
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.
4/15/15 11:35AM
The bull and bear cases for Gilead's first-quarter earnings hinge on discounts applied to prices of hepatitis C drug Harvoni and Sovaldi.
4/14/15 9:46AM
Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.
4/14/15 8:43AM
The verdict on an experimental stem cell therapy developed by Athersys to assist the recovery of stroke patients is coming on April 19.
4/13/15 9:32AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
4/10/15 6:01AM
As the CEO of a struggling stem-cell therapy company, Hedrick needs to don brightly colored pom-poms just to grab investors' attention.
4/8/15 2:51PM
Investors were treated to a hepatitis C data dump Wednesday morning ahead of a European liver disease meeting later in the month.
4/8/15 10:08AM
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
4/7/15 8:02AM
Plans to seek U.S. approval for the Ocular device, known as OTX-DP are now up in the air.
4/6/15 5:22PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
4/2/15 5:57AM
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
4/1/15 9:30AM
Current Sarepta Chief Medical Officer Ed Kaye is taking over the CEO role on an interim basis until a permanent chief can be found to replace Chris Garabedian.
3/31/15 9:57PM
Will the biotech bubble support the comeback of Introgen Therapeutics, one of the sector's largest disasters?
3/31/15 11:30AM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs